A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors

IRB/UVA Tracking #
20326
Contact First Name

Linsey Jackson

Phase
I
Primary purpose
Treatment
Cancer PI
Matthew Reilley
Status
OPEN TO ACCRUAL